From: SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome
Reference
Number of Patients
Mutation Prevalence
Impact on Survival
Atypical CML
[34]
70
17 (24.3%)
Yes (p-0.01)
[32]
60
19 (32.1%)
No (p-0.191)
Unclassifiable MDS/MPN
30
3 (10%)
NR
240
20 (9.3%)